NCT03151343View on ClinicalTrials.gov

SGLT-2 Inhibitor and Myocardial Perfusion, Function and Metabolism in T2 DM Patients at High Cardiovascular Risk

PHASE3CompletedINTERVENTIONAL

Enrollment

92

Participants

Timeline

Start Date

March 29, 2017

Primary Completion Date

May 22, 2020

Study Completion Date

May 22, 2020

Conditions

Type2 Diabetes Mellitus

Interventions

DRUG

Empagliflozin

Empagliflozin tablet

DRUG

Placebo Oral Tablet

Sugar pill, visually identical to active comparator

Trial Locations (1)

2730

Herlev og Gentofte Hospital, Herlev

Sponsors

Collaborators (1)

Danish Heart Foundation

All Listed Sponsors

collaborator

Danish Heart Foundation

OTHER

collaborator

Herlev and Gentofte Hospital

OTHER

collaborator

Rigshospitalet, Denmark

OTHER

lead

Caroline M Kistorp

OTHER